Team Science

Accelerating Research That Can Revolutionize Cancer Care

Our integrated research centers (IRCs) are launchpads for novel immunotherapies, vaccines and technologies that have strong commercial potential. By bringing together top talent from multiple disciplines and applying principles of business development to medical research, we enable the efficient translation of scientific insights into real-world solutions.

Notable achievements emerging from these centers include clinical trials leading to the 2017 FDA approval of a new immunotherapy drug for Merkel cell carcinoma (a rare and usually deadly skin cancer) and breakthrough research that laid the groundwork for a vaccine to prevent HPV, which can lead to cervical cancer. Discoveries from our IRCs have led to the creation of numerous startup companies, including Juno Therapeutics and Adaptive Biotechnologies.

Integrated Research Centers

A patient receives an infusion of immunotherapy treatment at the Seattle Cancer Care Alliance

Immunotherapy IRC

This center creates partnerships across Fred Hutch’s five scientific divisions to develop the next generation of lifesaving immunotherapies. Clinical trials take place in the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance. 

A researcher at the Pathogen-Associated Malignancies Integrated Research Center

Led by pioneering HPV researcher Dr. Denise Galloway, this center brings together experts in infectious diseases, cancer biology, immunology and immunotherapy to better understand, treat and prevent infection-related cancers.

Drs. Andrew Hsieh, Pete Nelson and Peggy Porter during an Oncoscape reception at Fred Hutchinson Cancer Research Center

Translational Data Science IRC

Advances in data science have added powerful ways for scientists to use data in their quest for new discoveries. This center facilitates collaboration between Fred Hutch researchers, data scientists and technology partners.